The english version of the website of the School of Medicine is under development

Δημοσίευση

KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study.

TitleKRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study.
Publication TypeJournal Article
Year of Publication2014
AuthorsNegru, S., Papadopoulou E., Apessos A., Stanculeanu D. Lucia, Ciuleanu E., Volovat C., Croitoru A., Kakolyris S., Aravantinos G., Ziras N., Athanasiadis E., Touroutoglou N., Pavlidis N., Kalofonos H. P., & Nasioulas G.
JournalBMJ Open
Volume4
Issue5
Paginatione004652
Date Published2014
ISSN2044-6055
Abstract

OBJECTIVES: Treatment decision-making in colorectal cancer is often guided by tumour tissue molecular analysis. The aim of this study was the development and validation of a high-resolution melting (HRM) method for the detection of KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer and determination of the frequency of these mutations in the respective populations.SETTING: Diagnostic molecular laboratory located in Athens, Greece.PARTICIPANTS: 2425 patients with colorectal cancer participated in the study.PRIMARY AND SECONDARY OUTCOME MEASURES: 2071 patients with colorectal cancer (1699 of Greek and 372 of Romanian origin) were analysed for KRAS exon 2 mutations. In addition, 354 tumours from consecutive patients (196 Greek and 161 Romanian) were subjected to full KRAS (exons 2, 3 and 4), NRAS (exons 2, 3 and 4) and BRAF (exon 15) analysis. KRAS, NRAS and BRAF mutation detection was performed by a newly designed HRM analysis protocol, followed by Sanger sequencing.RESULTS: KRAS exon 2 mutations (codons 12/13) were detected in 702 of the 1699 Greek patients with colorectal carcinoma analysed (41.3%) and in 39.2% (146/372) of the Romanian patients. Among the 354 patients who were subjected to full KRAS, NRAS and BRAF analysis, 40.96% had KRAS exon 2 mutations (codons 12/13). Among the KRAS exon 2 wild-type patients 15.31% harboured additional RAS mutations and 12.44% BRAF mutations. The newly designed HRM method used showed a higher sensitivity compared with the sequencing method.CONCLUSIONS: The HRM method developed was shown to be a reliable method for KRAS, NRAS and BRAF mutation detection. Furthermore, no difference in the mutation frequency of KRAS, NRAS and BRAF was observed between Greek and Romanian patients with colorectal cancer.

DOI10.1136/bmjopen-2013-004652
Alternate JournalBMJ Open
PubMed ID24859998
PubMed Central IDPMC4039802

Contact

Secretariat of the School of Medicine
 

Connect

Schoole of Medicince presence in social networks
Follow Us or Connect with us.